Epidemiological profile and risk factors of HIV and HBV/HCV co‐infection in Fujian Province, southeastern China. Issue 3 (2nd September 2016)

• Record Type: Journal Article
• Authors: Wu, Shouli; Yan, Pingping; Yang, Tianfei; Wang, Zhenghua; Yan, Yansheng
• Is Part Of: Journal of medical virology. Volume 89:Issue 3(2017)
• Page Start: 443
• Page End: 449
• Publication Date: 2016-09-02
• Subjects: HIV -- HBV -- HCV -- co‐infection -- risk factor -- Southeastern China; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.24666
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract : This study aimed to investigate the epidemiological features of HIV‐infected subjects co‐infected with HBV/HCV in Fujian Province, southeastern China, and identify the risk factors. Blood samples were collected from 2, 028 HIV antibody‐positive subjects in Fujian Province. Serum HBsAg and anti‐HCV antibody were detected, and CD4 + T cell count was measured. Of the 2, 028 subjects, the prevalence of HIV‐HBV, HIV‐HCV, and HIV‐HBV‐HCV co‐infections was 16.22%, 3.7%, and 0.79%, respectively. Man (OR = 1.912, 95% CI: 1.371–2.667), key population (OR = 0.756, 95% CI: 0.57–0.976) and detainee (OR = 0.486, 95% CI: 0.259–0.909) were risk factors of HIV‐HBV co‐infection, and man (OR = 2.227, 95% CI: 1.096–4.525), minority (OR = 5.04, 95% CI: 1.696–14.98), junior high school or lower education (OR = 2.32, 95% CI: 1.071–5.025), intravenous drug use (OR = 38.46, 95% CI: 11.46–129.11) and detainee (OR = 5.687, 95% CI: 2.44–13.25) were risk factors of HIV‐HCV co‐infection. In addition, a lower mean CD4 + T cell count was measured in HIV/HBV and HIV/HCV co‐infected subjects than in HIV‐infected subjects among the untreated individuals, while in the treated populations, a higher mean CD4 + T cell count was detected in HIV/HBV and HIV/HCV co‐infected subjects than in HIV‐infected subjects. HIV co‐infection with HBV or HCV, notably HIV‐HBV co‐infection, is widespread in southeastern China. Hepatitis virus screening should be included in monitoring of HIV infection, and HIV and hepatitis virus co‐infection should be considered during the development of HIV antiretroviral therapy scheme. J. Med. Virol. 89:443–449, 2017 . © 2016 Wiley Periodicals, Inc.